The effects of prior calcium channel blocker therapy on creatine kinase-MB levels after percutaneous coronary interventions

Abstract

Background:

Use of intracoronary calcium channel blockers (CCBs) during percutaneous coronary intervention (PCI) has been shown to have favorable effects on coronary blood flow. We aimed to investigate the effects of CCBs administrated perorally on creatine kinase-MB (CK-MB) levels in patients undergoing elective PCI.

Methods:

A total of 570 patients who underwent PCI were evaluated for CK-MB elevation. Patients who were on CCB therapy when admitted to the hospital constituted the CCB group. No CCBs were given to the rest of the patients during the periprocedural period and these patients served as the control group. Blood samples for CK-MB were obtained before and at 6 h, 24 h, and 36 h after the procedure.

Results:

217 patients were in the CCB group (mean age 60.2 ± 9.3 years, 162 males), and 353 were in the control group (mean age 60.0 ± 10.1 years, 262 males). CK-MB levels increased above the normal values in 41 patients (18.9%) of the CCBs group and in 97 patients (27.5%) of the control group (p = 0.02). Median CK-MB levels were significantly higher in the control group for all studied hours (for all p < 0.05).

Conclusions:

Prior oral CCB therapy may have favorable effects in preventing myocyte necrosis after elective PCI.

Keywords:

• calcium channel blockers
• myonecrosis
• percutaneous coronary interventions

Introduction

Elevation of creatine kinase-MB (CK-MB) isoenzyme due to myonecrosis after elective percutaneous coronary intervention (PCI) can be detected in 5%–30% of patients (Abdelmeguid and Topol 1996; Califf et al 1998; Simoons et al 1999; Tardiff et al 1999; Akkerhuis et al 2002). Factors related to the procedure such as side-branch occlusion, intimal dissection, and distal embolization have been suggested as possible causes of increased cardiac enzymes after PCI (Abdelmeguid et al 1996; Simoons et al 1999; Tardiff et al 1999). Other possible mechanisms are coronary vasospasm and no reflow phenomenon (Demir et al 2002). Several studies have reported that elevated cardiac markers such as CK-MB and cardiac troponins (cTn) after PCI is associated with an increase in cardiac mortality and morbidity during follow-up (Abdelmeguid et al 1996; Califf et al 1998; Simoons et al 1999; Tardiff et al 1999).

Previous studies suggested intracoronary administration of calcium channel blockers (CCBs) is effective for resolving coronary spasm and no-reflow phenomenon (Michaels et al 2002; Werner et al 2002). To our knowledge there is no data about the effects of administration of oral CCBs on CK-MB levels after PCI.

The aim of this study was to investigate the effect of CCBs used perorally on CK-MB levels in patients undergoing elective PCI.

Methods

Patient population and study protocol

The study was approved by the local Ethics Committee of Baskent University Hospital in Ankara, Turkey. All patients undergoing PCI between December 2000 and December 2005 at our institution were evaluated for eligibility for this study, and all provided written informed consent before participating. Patients who were taking a CCB at the discretion of their own primary physician on admission were noted and the drug at the same dose was continued during the hospitalization period and thereafter. No CCBs were prescribed to the patients who were not already on one. Patients presenting with acute or recent myocardial infarction (MI) within 7 days, renal insufficiency with creatinine levels higher than 1.4 mg/dL, and those in whom use of a special device (laser, rotational atherectomy, brachy-therapy, etc) was planned were excluded. A total of 570 patients with elective PCI history were included in the study (mean age 60.1 ± 9.8 years, 74.4% males). The patients who were on a CCB on admission constituted the CCB group while the others served as controls.

There were 217 patients (mean age 60.2 ± 9.3 years, 74.7% males) in the CCB group and 353 patients (mean age 60.0 ± 10.1 years, 74.2% males) in the control group. Ninety percent of the patients in the CCB group were receiving diltiazem 180 mg/day, whereas others were receiving amlodipine 10 mg/day, felodipine 4 mg/day, or verapamil 240 mg/day.

All interventions were performed via the femoral approach. The choices of technique (percutaneous transluminal coronary angioplasty [PTCA], PTCA + stent, stent only) and adjunctive pharmacologic management were at the discretion of the operator according to the lesion characteristics. Angiographic success was defined as a residual stenosis of the treated lesion <50% on visual estimation and -in case of stenting- desired position of the stent with Thrombolysis in Myocardial Infarction grade III flow. Commercially available drug-eluting and bare metal stents were used. All patients received aspirin 300 mg/day, and 75-mg maintance dose of clopidogrel.

Laboratory analyses

Creatine kinase-MB isoform was measured routinely before PCI and 6, 24, and 36 h after PCI. Additional measurements were done for clinical indications. Levels of CK-MB were determined by an immunoinhibition assay (Roche Diagnostics, GmbH, Mannheim, Germany). The reference limit for CK-MB with this method is 0–24 U/L. CK-MB levels were considered elevated if the measurement was above the normal limit in any of the follow-up measurements. The CK-MB levels were further subdivided into 1 to 3 times (24–72 U/l) and 3 to 5 times (73–120 U/l) of the normal levels.

Statistical analysis

The statistical package, SPSS version 9.0 (SSPS Inc., Chicago, IL, USA) was used for statistical analyses. Continuous variables with normal distribution were compared using the unpaired Student’s t-test and were presented as the mean ± SD. Continuous variables with abnormal distributions were compared using the Mann-Whitney U test, and CK-MB results for each group were expressed as median and interquartile ranges. The CK-MB elevation within the groups were compared with the general lineer model for repeated measures test. Categorical data were reported as frequencies and percentages. Comparisons between categorical variables were performed using Fisher exact tests if any subgroup consisted of five or fewer items; otherwise, chi-square tests were used. Values for p less than 0.05 were considered statistically significant.

Results

Baseline clinical and laboratory characteristics were similar between two groups (Table 1). The angiographic and procedural characteristics of the patients are listed in Table 2. No differences were observed between the groups (all p > 0.05). No patients died during the study period. Major adverse effects which included coronary artery spasm or dissection, the need for blood transfusion and subacute occlusion were not different between the groups (Table 2).

Table 1 Baseline clinical and laboratory features of CCB and control groups

	CCB group n = 217	Control group n = 353	P value
Clinical characteristics
Age (year)	60.2 ± 9.3	60.0 ± 10.1	0.79
Sex, male, n (%)	162 (74.7)	262 (74.2)	0.90
SAP/USAP, n (%)	140 (64.5)/77 (35.5)	232 (65.7)/121 (34.3)	0.77
Diabetes mellitus, n (%)	50 (23.0)	102 (28.9)	0.14
Hypertension, n (%)	137 (63.1)	193 (54.7)	0.05
Dyslipidemia, n (%)	135 (62.2)	217 (61.5)	0.67
Smoking, n (%)	92 (42.4)	142 (40.2)	0.78
History of PCI, n (%)	49 (22.6)	53 (15.0)	0.05
History of CABG, n (%)	43 (19.8)	58 (16.4)	0.33
Mean LVEF, %	47 ± 11	48 ± 12	0.69
Drugs
ACE inhibitors, n (%)	73 (33.6)	149 (42.2)	0.05
Statins, n (%)	134 (61.8)	228 (64.6)	0.49
Nitrates, n (%)	66 (30.4)	131 (37.1)	0.11
Laboratory Findings
Fasting blood sugar levels (mg/dL)	111.9 ± 42.2	115.3 ± 45.6	0.45
Blood urea nitrogen levels (mg/dL)	17.9 ± 5.9	18.3 ± 6.5	0.65
Creatinine (mg/dL)	1.1 ± 0.8	1.1 ± 0.6	0.99
LDL cholesterol (mg/dL)	112.3 ± 39.3	111.3 ± 38.6	0.79
Triglyceride (mg/dL)	154.5 ± 76.6	164.5 ± 94.5	0.28
Hemoglobin (g/dL)	14.1 ± 1.6	13.7 ± 1.7	0.06

Abbreviations: CCB, calcium channel blocker; PCI, percutaneous coronary interventions; CABG, coronary artery bypass graft surgery; LVEF, left ventricular ejection fraction; SAP, stable angina pectoris; USAP, unstable angina pectoris; ACE, angiotensin-converting enzyme; LDL, low-density lipoprotein.

Table 2 Details of PCI procedures between groups

	CCB group n = 217	Control group n = 353	P value
Dilated coronary artery
Left anterior descending, n (%)	89 (41.0)	174 (49.3)	0.05
Left circumflex, n (%)	79 (36.4)	118 (33.4)	0.46
Right coronary artery, n (%)	74 (34.1)	100 (28.3)	0.15
Graft lesion, n (%)	13.0 (6.0)	13 (3.7)	0.19
Multi-vessel PCI, n (%)	41 (18.9)	60 (17.0)	0.56
Drug-eluting stent, n (%)	5 (2.3)	11 (3.1)	0.79
Stent used per procedure, n (%)	1.3 ± 0.4	1.3 ± 0.4	0.77
Mean stent length (mm)	13.3 ± 6.5	13.3 ± 6.7	0.92
Mean stent diameter (mm)	2.9 ± 0.4	3.0 ± 0.4	0.16
Total inflation time, s	124.2 ± 85.7	114.8 ± 83.3	0.23
Max inflation pressure, atm	11.8 ± 5.4	11.8 ± 4.1	0.99
Spasm, n (%)	6 (2.8)	6 (1.7)	0.39
Dissections, n (%)	3 (1.4)	6 (1.7)	1.00
Blood transfusion, n (%)	2 (0.9)	3 (0.8)	1.00
Subacute occlusion, n (%)	5 (2.3)	7 (2.9)	0.77

Abbreviations: CCB, calcium channel blockers; CK-MB, creatine kinase-MB; PCI, percutaneous coronary interventions.

Baseline CK-MB levels were similar in patients in the CBB and control groups (Table 3). During in-hospital follow-up period for 36 hours, CK-MB levels increased above the normal values in 41 patients (18.9%) of the CCBs group and in 97 patients (27.5%) of the control group (p = 0.02). The incidence of CK-MB elevation 1 to 3 times normal was 18.9% vs 26.9% (p = 0.03); 3 to 5 times normal was 0.5% vs 3.1% (p = 0.03) in the CCB and control groups, respectively. Three patients (0.8%) in the control group and none in the CCB group had CK-MB levels 5 times normal (p = 0.29). The diagnosis of postprocedural MI was based on either an increase in CK-MB 3 times the upper limit of normal, or development of pathologic Q waves in 2 or more contiguous electrocardiographic leads.

Table 3 Median (interquartile range) CK-MB levels of the groups during follow-up

	CCB group n = 217	Control group n = 353	P value
Baseline CK-MB, U/L	11.0 (7.0–16.0)	12.0 (8.0–17.0)	0.13
After PCI, 6th hours CK-MB, U/L	14.0 (8.2–21.0)	15 (10.2–21.0)	0.03
After PCI, 24th hours CK-MB, U/L	13.0 (9.0–19.7)	16.0 (11.0–22.0)	0.001
After PCI, 36th hours CK-MB, U/L	13.0 (8.0–20.0)	15.0 (10.0–24.0)	0.000

Abbreviations: CCB, calcium channel blockers; CK-MB, creatine kinase-MB; PCI, percutaneous coronary interventions.

The median CK-MB levels were significantly higher in the control group compared with CCBs group at 6 h, 24 h, 36 h after PCI (Table 3). The elevations of CK-MB levels were statistically significant within the groups (both p < 0.001) (Figure 1).

Figure 1 Mean CK-MB levels of the groups during follow-up.

Abbreviations: CCB, calcium channel blockers; CK-MB, creatine kinase-MB.

Discussion

Both previous retrospective studies and prospective randomized trials have shown that development of new treatment strategies like intracoronary nitrate infusion, oral statins, glycoprotein IIb/IIIa inhibitors and adenosine reduce ischemic complications, death, nonfatal myocardial infarction, and release of CK-MB after coronary interventions when compared with placebo (EPISTENT 1998; Kurz et al 2000; Desmet et al 2002; Hermann et al 2002; Aronow et al 2002a, 2002b; Wang et al 2003; Pasceri et al 2004). Moreover, recently published trials demonstrated beneficial effects of beta blockers on CK-MB levels in patients with PCI as well (Roberts et al 1991; Sharma et al 2000; Ellis et al 2001; Wang et al 2003; Sato et al 2004).

Several studies have shown that intracoronary administration of CCBs reduces procedural myonecrosis in patients undergoing elective or urgent PCI. Demir and colleagues (2002) and Werner and colleagues (2002) have reported that intracoronary verapamil has favourable effects on coronary vasospasm and no-reflow phenomenon in patients with primary PTCA for acute MI. In VAPOR (VAsodilator Prevention On no-Reflow) trial intragraft verapamil was given pre-PCI to prevent no-reflow and there was a trend toward improved myocardial perfusion as assessed using the TIMI myocardial perfusion grade (TMPG) (Michaels et al 2002). In the VESPA (VErapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty) trial, 240 mg/d verapamil administered for six months after PCI reduced the incidence of need for repeat target vessel revascularization (Bestehorn et al 2004). A new recent meta-analysis of the two largest trials, Nisoldipine in Coronary artery Disease in Leuven (NICOLE) and Coronary Angioplasty Amlodipine in Restenosis Study (CAPARES), found that CCBs improved long term clinical outcome and reduced the need for target vessel revascularization when compared with placebo (Dens et al 2003). It was concluded that this might be due to the antiproliferative properties of CCBs which were demonstrated in in vitro experiments (Yang et al 1993; Voisard et al 1997). Moreover, the recently published trial by Matthews and colleagues (2005) demonstrated that using intracoronary CCB at the time of PCI result in lower postprocedural creatine phosphokinase (CPK) values and smaller areas under the CPK curve.

The aim of our study was to evaluate the relationship between systemic administration of CCBs and the elevation of CK-MB suggestive of myonecrosis. The results indicate that in elective PCI, per procedural CCBs usage may be associated with reduced CK-MB release. The cardioprotective effects of CCBs’ observed in our study can be explained by several mechanisms.

Klein and colleagues (1989) have found that the development of infarcts were significantly delayed and the mean infarct sizes were smaller with intracoronary infusion of diltiazem, verapamil or nifedipine indicating that CCBs increase the ischemic tolerance significantly by their effects on calcium homeostasis in the setting of acute ischemia during baloon inflations at PCI.

The CCBs may also protect the patients against fatal or nonfatal infarction via their platelet-inhibiting effects. Folts (1997) have reported that IV amlodipine administration was found to be protective against exacarbation of coronary thrombosis by epinephrine in dog model of experimental coronary artery thrombosis.

CCBs’ may also improve nitric oxide (NO) release and improve endothelial functions (Taddei et al 2001). The ENCORE Investigators (Evaluation of Nifedipine and Cerivastatin on Recovery of Coronary Endothelial function) have reported that 30 to 60 mg/d nifedipine treatment over a 6 month period improved coronary endothelial function in the most constricted segment. Mechanisms that could be targeted by CCBs’ include antioxidative properties and effects on endothelial nitric oxide synthase (eNOS) expression and activity (ENCORE 2003). The present study was not designed to evaluate the mechanism by which CCBs might prevent myonecrosis after PCI and we do not know the factors affecting our results.

Study limitations

There are several limitations of this study. This study is a nonrandomized study with lack of clinical follow-up. The patient numbers in the present study are small and lack the ability of a prospective randomized trial to minimize differences between the groups. The groups were formed before the study and the patients who were receiving CCBs at the discretion of their physician constituted the drug group, so the patients used different types and doses of CCBs. We did not collect any data on myocardial perfusion by angiography (TIMI frame count, myocardial perfusion blush scores), dynamic ST-segment changes to identify a relation with no-reflow at any time during mechanical perfusion. The number of patients with CK-MB elevations in both groups was small, and all patients at both groups had a very low incidence of MI after PCI.

Conclusion

Despite these limitations, the study points out that systemic administration of CCBs may be associated with reduced CK-MB release after elective PCIs. Long-term prospective randomized trials are required to confirm the effects of CCBs on myocyte necrosis in patients undergoing elective PCI.

Disclosure

None of the authors have associations that might pose a conflict of interest. No financial support from any organization was used.